Placebo for Elecoglipron (AZD5004)
Sponsors
AstraZeneca AB
Conditions
Chronic kidney disease (CKD) in adultsHeart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF);
on background SGLT2i.Participants Living with Obesity or Overweight with at least 1 comorbidity with or without Type 2 Diabetes Mellitusirrespective of T2DM status; background SGLT2i dapagliflozin 10 mg as GDMT.type 2 diabetes mellituswith specified ranges of eGFR and albuminuria (UACR)
Phase 3
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
Not yet recruitingCTIS2025-523994-41-00
Target: 260Updated: 2026-07-24
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
Not yet recruitingCTIS2025-524688-19-00
Target: 325Updated: 2026-07-27
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
Not yet recruitingCTIS2026-526304-79-00
Target: 787Updated: 2026-07-30
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron compared with Placebo in Adults with Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)
Not yet recruitingCTIS2025-523940-12-00
Target: 93Updated: 2026-08-05
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)
Not yet recruitingCTIS2025-523941-81-00
Target: 190Updated: 2026-08-05
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Placebo in Adults with Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
Not yet recruitingCTIS2025-523935-20-00
Target: 130Updated: 2026-08-04